E9 Glucose regulation

Topic

Blood glucose regulation operates via negative feedback, maintaining plasma glucose concentration within a relatively narrow range. When glucose levels rise, pancreatic beta cells detect the change and secrete insulin. This signal promotes glucose uptake by cells and lowers plasma glucose concentration. When glucose levels drop too low, alpha cells secrete glucagon, which exerts the opposite effect and promotes a rise in glucose levels. Insulin and glucagon thus act as opposing signals that stabilize blood glucose.

The liver plays a central role in this control mechanism. It can produce glucose via gluconeogenesis and release it into the bloodstream, responding to the balance between insulin and glucagon. When insulin predominates, hepatic glucose production decreases; when glucagon predominates, gluconeogenesis and glucose release increase. Regulation therefore depends on both tissue glucose uptake and the amount of glucose the liver releases into the blood.

The tissue response to a given amount of insulin is known as insulin sensitivity. This can be assessed by administering intravenous glucose and monitoring glucose and insulin concentrations over several hours. Analyzing these levels makes it possible to distinguish between tissue insulin sensitivity and the beta cells' ability to respond rapidly to a rise in glucose by secreting insulin. A loss of sensitivity implies that a larger amount of insulin is required to achieve an equivalent metabolic response.

While these tests describe the system's function at a specific moment, glycated hemoglobin reflects blood glucose levels over a longer period. Glucose binds spontaneously and permanently to hemoglobin in red blood cells; the higher the plasma glucose concentration has been, the greater the proportion of accumulated glycated hemoglobin. Since erythrocytes remain in circulation for months, this measurement reflects the average blood glucose level over the preceding months and serves as a key indicator of diabetes control.

Insulin sensitivity can be measured more precisely using a technique in which insulin is administered at a constant rate while glucose is simultaneously infused to maintain stable blood glucose levels. The amount of glucose required to counteract the effect of a given dose of insulin directly reflects tissue sensitivity: if a large amount of glucose is needed, sensitivity is high; if little is needed, insulin resistance is higher.

When the body stops producing sufficient insulin, external administration aims to replicate the pancreas's physiological pattern. Normally, there is continuous basal secretion, supplemented by rapid spikes associated with meals. Long-acting insulins aim to maintain a relatively constant level over many hours and replace the basal component, whereas rapid-acting insulins produce brief spikes designed to control the rise in glucose caused by food intake.

Closed-loop systems, or artificial pancreases, take this principle a step further. A sensor continuously measures glucose concentration, and a control system uses this information to automatically adjust the amount of insulin delivered by a pump. If glucose levels rise, the system increases delivery; if they fall, it reduces it. In this way, it artificially replicates part of the natural pancreas's feedback loop.

Overall, glucose regulation depends on the interplay between pancreatic secretion of insulin and glucagon, hepatic glucose production, and tissue sensitivity to insulin. Dynamic tests allow for the assessment of the system's immediate response, while glycated hemoglobin provides a summary of control over previous months. When natural regulation proves insufficient, various insulin formulations and closed-loop systems aim to progressively reconstruct the same physiological principle: measuring glucose changes and adjusting the response to return levels to the normal range.

ID:2252